These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29714580)

  • 1. Advancing Drug Safety Through Prospective Pharmacovigilance.
    Pitts PJ; Le Louet H
    Ther Innov Regul Sci; 2018 Jul; 52(4):400-402. PubMed ID: 29714580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 21st-Century Oncology Drug Safety via New-Age Regulatory Standards and Practices.
    Pitts PJ; Le Louet H; Katz G
    Ther Innov Regul Sci; 2019 Sep; 53(5):701-705. PubMed ID: 30392396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From the Valley of Death to the Crossroads of Opportunity: A Discussion of Evolving Benefit/Risk Evaluation Standards.
    Pitts PJ; Brady P
    Ther Innov Regul Sci; 2018 Sep; 52(5):531-536. PubMed ID: 29763344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance strategy: opportunities for cross-national learning.
    Fermont I
    Isr J Health Policy Res; 2019 Jun; 8(1):54. PubMed ID: 31217025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance in resource-limited countries.
    Olsson S; Pal SN; Dodoo A
    Expert Rev Clin Pharmacol; 2015; 8(4):449-60. PubMed ID: 26041035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The International Working Group on New Developments in Pharmacovigilance: Advancing Methods and Communication in Pharmacovigilance.
    Cooper D; Platt RW; van Hunsel F; Davies M; Yeomans A; Lane S; Shakir S
    Clin Ther; 2024 Jan; ():. PubMed ID: 38233256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Learning the effects of psychotropic drugs during pregnancy using real-world safety data: a paradigm shift toward modern pharmacovigilance.
    Lupattelli A; Spigset O; Nordeng H
    Int J Clin Pharm; 2018 Aug; 40(4):783-786. PubMed ID: 29948744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
    Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements.
    Maigetter K; Pollock AM; Kadam A; Ward K; Weiss MG
    Int J Health Policy Manag; 2015 Mar; 4(5):295-305. PubMed ID: 25905480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
    Francisca RDC; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
    Expert Opin Drug Saf; 2018 Oct; 17(10):975-982. PubMed ID: 30107752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
    Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial Intelligence, Real-World Automation and the Safety of Medicines.
    Bate A; Hobbiger SF
    Drug Saf; 2021 Feb; 44(2):125-132. PubMed ID: 33026641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacovigilance in Crisis: Drug Safety at a Crossroads.
    Price J
    Clin Ther; 2018 May; 40(5):790-797. PubMed ID: 29605513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial Intelligence and the Future of the Drug Safety Professional.
    Danysz K; Cicirello S; Mingle E; Assuncao B; Tetarenko N; Mockute R; Abatemarco D; Widdowson M; Desai S
    Drug Saf; 2019 Apr; 42(4):491-497. PubMed ID: 30343417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.